🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

“I shouldn't be here” It's not that I don't feel like I belong here at #GI24 These are my people It's more of a recognition of my personal statistics. A thread 1/7 🧵

(Older) Prospective trial Boswellia University of Tübingen · 11 Gliomas, 1 Brain Met w/progressive edema · 29% had ↓↓tumor edema · 60% had ↓↓treatment-related leukoencephalopathy

Study that went under the radar at ASCO. WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases. Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing

Stergios J. Moschos, MD, of UCLA discusses how the use of bridging therapy can enhance the efficacy of adoptive T-cell therapies for patients with melanoma. Watch the full video here: hubs.li/Q03sRSRc0

🔥 Breakthrough in HR+HER2– Breast Cancer! 🧬 In I-SPY2 trial (n=395), ImPrint, an mRNA-based immune classifier, predicted response to neoadjuvant immunotherapy (IO) in high-risk HR+HER2– patients. 🔹 pCR with IO: ➡️ 75% in ImPrint+ vs 17% in ImPrint– ➡️ >90% pCR in best

Recent findings demonstrate disparities in the receipt of palliative-intent interventions among disaggregated Hispanic subgroups. Disaggregated research to further characterize these disparities and their drivers is needed. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… OncoAlert Edward Christopher "Chris" Dee, MD #PallOnc

Our manuscript highlighting the design, goals, and experiences of the MBCRC Advocate Researcher Program (MARP), which focused on building meaningful, bidirectional partnerships between advocates and researchers was published in npj Journals breast. nature.com/articles/s4152…

NIH will reinstate 900 grants in response to court order | Science | AAAS science.org/content/articl…

Huge thanks to our collaborators and funders - DoD, METAvivor, @Americancancer, @NIH/NCI … And big congrats to Xiaoding Hu for leading this impactful work!👏👏👏MD Anderson Cancer Center

A new study led by Eva Berlin, MD, provides reassurance that modern #BreastCancer #Radiotherapy does not show any clinically overt signs of effect to systolic function of the heart, likely due to low heart dose. The ASCO Post spr.ly/60114gpNx

#DYK

Learn how world-class lung cancer screening is hitting the road with Ohio State's new mobile unit. health.osu.edu/health/cancer/…

FDA Ends Safety Program for Certain CAR T-Cell Therapies | Cancer Discovery News | American Association for Cancer Research aacrjournals.org/cdnews/news/24…

The Lobular Breast Cancer Alliance, in collaboration with AACR, will offer 5 scholar awards to recognize the best lobular breast cancer abstracts selected for poster presentation at #SABCS25. Submit an abstract by July 9 to be considered: brnw.ch/21wTNgz Lobular Breast Cancer Alliance

Key takeaways from the American Society of Clinical Oncology (ASCO) conference: 🔑 New targeted therapies show promise for hormone-positive cancers 🔑 Lower drug doses may be equally effective 🔑 Long-term hormone therapy benefits confirmed Read more: mbca.me/4kkc9w1

Dr Sarah Tolaney (Sara Tolaney) discusses #ASCENT04 Data in First-Line PD-L1+ metastatic #TNBC with Targeted Oncology. Watch the video here: targetedonc.com/view/dr-tolane…

Explore the latest breakthroughs in melanoma research, see how innovative treatments and science are leading to better outcomes for patients. Discover the newest case studies supported by MRA and learn how research is driving hope forward at: curemelanoma.org/patient-eng/ca…

I will be discussing novel updates in first-line HER2+ Metastatic Breast Cancer! Gathering my thoughts on DB-09 and PATINA now.

We are deeply saddened to hear about the passing of Shirley Mertz, a tireless and passionate patient advocate who dedicated her life to advancing the cause of all Advanced Breast Cancer patients around the world. Her legacy and impact will never be forgotten.